CD19 CAR T-Cell Dosing for Relapsed LBCL With Lower Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for relapsed or refractory large B-cell lymphoma (LBCL) after first-line chemoimmunotherapy, particularly in subjects ineligible for hematopoietic stem cell transplantation (HSCT), have limited efficacy and high toxicity, with low overall response rates and short event-free survival.
Innovation Solution
Administering a dose of autologous CD19-directed genetically modified T cells, comprising CD4+ and CD8+ T cells expressing a chimeric antigen receptor (CAR) at a 1:1 ratio, within a specific cell count range, to subjects with LBCL who have relapsed or are refractory to first-line therapy, often accompanied by a lymphodepleting regimen.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard of care therapies are used for relapsed or refractory LBCL, then treatment can be administered, but overall response rates are low and event-free survival is short
Solution Approach 1:
The patent changes the therapeutic parameter from conventional chemotherapy to CAR T cell therapy with specific dosing parameters (44×10^6 to 120×10^6 CAR-positive viable T cells). This parameter change results in improved overall response rates (ORR) and extended event-free survival (EFS) compared to standard of care therapies.
2Reliability
If higher doses of CAR T cells are administered, then response rate may improve, but toxicity increases
Solution Approach 1:
The patent optimizes the dose parameter to a specific range (44×10^6 to 120×10^6 CAR-positive viable T cells) that achieves effective response rates while managing toxicity. This parameter optimization balances therapeutic efficacy with safety, avoiding both under-dosing and excessive toxicity.
Solution Approach 2:
The patent employs a controlled level of T cell activation and expansion through the specified dosing range, achieving sufficient therapeutic effect without excessive activation that would lead to severe toxicity. The dose is calibrated to provide partial action sufficient for efficacy while avoiding excessive action that causes harm.
3Power
If CD8+ T cells are used alone, then cytotoxic activity is high, but immune regulation is insufficient
Solution Approach 1:
The patent combines CD4+ T cells and CD8+ T cells in a single therapy formulation, merging the regulatory functions of CD4+ cells with the cytotoxic functions of CD8+ cells. This combination achieves both high cytotoxic activity against tumor cells and proper immune regulation, resolving the contradiction between power and stability.
Solution Approach 2:
The dual T cell population formulation provides multi-functionality: CD8+ T cells provide cytotoxic killing while CD4+ T cells provide immune regulation and support. Together, they create a universal therapeutic agent that performs multiple functions simultaneously, achieving both high power and stability.
Data Source
AI summary
Provided are adoptive cell therapy involving the administration of doses of cells for treating subjects with certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is a large B cell lymphoma (LBCL) relapsed or refractory to first-line chemoimmunotherapy.